

Answering reviewers

Dear Editors and Reviewers:

Thank you for your letter and for the reviewers' comments concerning our manuscript entitled "Therapeutic tumor vaccines - a rising star to benefit cancer patients" (**Manuscript NO: 66932**). Those comments are all valuable and very helpful for revising and improving the paper, which we believe that have greatly improved the quality of the paper. We have studied comments carefully and have made a revision according to the comments and make point-by-point responses to the issues raised in the peer-review report(s), which are listed below:

Reviewer #1:

Scientific Quality: Grade A (Excellent)

Language Quality: Grade A (Priority publishing)

Conclusion: Minor revision

Specific Comments to Authors: General comments: This is a well-written and thoughtfully organized overview of the current status of the development of therapeutic tumor vaccines. The main types, tumor cell vaccines, dendritic cell vaccines, polypeptide vaccines, viral/bacterial vector vaccines, and nucleic acid vaccines are accurately described. Their advantageous features as well as impediments are discussed and the results emerging from recent and current clinical trials highlighted. Specific comments: 1. It would be good to comment on how could the current massive use of mRNA vaccines for covid-19 immunization influence further progress with the use of mRNA tumor vaccines. 2. In the References section, listing of the reference #32 is incomplete.

Author Response: Thank you for your positive comments. We are grateful for the time and energy you expended on our behalf. The correction was made as requested.

1. Your suggestion is truly helpful and valuable, and we have added content about how could the current massive use of mRNA vaccines for COVID-19 immunization influence further progress with the use of mRNA tumor vaccines in the article. The relevant content can be seen in section **4.3 FixVac (BNT111)** of the article and the second-to-last paragraph of the **CONCLUDING REMARKS**. We have added two tables (**Table 3 and Table 4**) about the current clinical status of mRNA tumor vaccines and COVID-19 vaccines as well.
2. The previous reference #32 is indeed the wrong format, so we have checked reference #32 and completed it.

EDITORIAL OFFICE'S COMMENTS

- (1) **Science editor:** 1 Scientific quality: The manuscript describes a academic activity report of the therapeutic tumor vaccines - a rising star to benefit cancer patients. The topic is within the scope of the AIC. (1) Classification: Grade A; (2) Summary of the Peer-Review Report: This is a well-written and thoughtfully organized overview of the current status of the development of therapeutic tumor vaccines. The main types, tumor cell vaccines, dendritic cell vaccines, polypeptide vaccines, viral/bacterial vector vaccines, and nucleic acid vaccines are accurately described. However, the questions raised by the reviewer should be answered; and (3) Format: There are 2 tables and 1 figure. (4) References: A total of 43

references are cited, including 5 references published in the last 3 years; (5) Self-cited references: There are no self-cited references; and (6) References recommend: The authors have the right to refuse to cite improper references recommended by peer reviewer(s), especially the references published by the peer reviewer(s) themselves. If the authors found the peer reviewer(s) request the authors to cite improper references published by themselves, please send the peer reviewer's ID number to the editorialoffice@wjgnet.com. The Editorial Office will close and remove the peer reviewer from the F6Publishing system immediately. 2 Language evaluation: Classification: Grade A. 3 Academic norms and rules: No academic misconduct was found in the Bing search. 4 Supplementary comments: This is an invited manuscript. No financial support was obtained for the study. The topic has not previously been published in the AIC.

[Author Response: Thank you for your comment. We have taken into consideration the comments of the first reviewer and the questions raised by the reviewer have been answered above.](#)

5 Issues raised: (1) The "Author Contributions" section is missing. Please provide the author contributions; (2) The authors did not provide original pictures. Please provide the original figure documents. Please prepare and arrange the figures using PowerPoint to ensure that all graphs or arrows or text portions can be reprocessed by the editor; (3) PMID and DOI numbers are missing in the reference list. Please provide the PubMed numbers and DOI citation numbers to the reference list and list all authors of the references. Please revise throughout; and (4) Please obtain permission for the use of picture(s). If an author of a submission is re-using a figure or figures published elsewhere, or that is copyrighted, the author must provide documentation that the previous publisher or copyright holder has given permission for the figure to be re-published; and correctly indicating the reference source and copyrights. For example, "Figure 1 Histopathological examination by hematoxylin-eosin staining (200 ×). A: Control group; B: Model group; C: Pioglitazone hydrochloride group; D: Chinese herbal medicine group. Citation: Yang JM, Sun Y, Wang M, Zhang XL, Zhang SJ, Gao YS, Chen L, Wu MY, Zhou L, Zhou YM, Wang Y, Zheng FJ, Li YH. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease. *World J Gastroenterol* 2019; 25(34): 5105-5119. Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc[6]". And please cite the reference source in the references list. If the author fails to properly cite the published or copyrighted picture(s) or table(s) as described above, he/she will be subject to withdrawal of the article from BPG publications and may even be held liable.

[Author Response: \(1\) We have added the author contributions.](#)
[\(2\) We will provide original pictures and upload original figure documents according to relevant requirements.](#)
[\(3\) We have revised throughout the reference list and added the PubMed numbers and DOI citation numbers to it and listed all authors.](#)
[\(4\) As is indicated in the legend, figure resource was downloaded from the open access website \(<https://ClinicalTrials.gov>\), and the histogram was made by author Qian Wei](#)

[according to distribution of clinical trials on the map.](#)

6 Recommendation: Conditional acceptance.

- (2) **Company editor-in-chief:** I have reviewed the Peer-Review Report, full text of the manuscript, and the relevant ethics documents, all of which have met the basic publishing requirements of the Artificial Intelligence in Cancer, and the manuscript is conditionally accepted. I have sent the manuscript to the author(s) for its revision according to the Peer-Review Report, Editorial Office's comments and the Criteria for Manuscript Revision by Authors.

6 STEPS FOR SUBMITTING REVISED MANUSCRIPT

Step 1: Author Information

Please click and download the Format for authorship, institution, and corresponding author guidelines, and further check if the authors names and institutions meet the requirements of the journal.

Step 2: Manuscript Information

Please check if the manuscript information is correct.

Step 3: Abstract, Main Text, and Acknowledgements

(a) Guidelines for revising the content: Please download the guidelines for Original articles; Review articles; and Case report articles for your specific manuscript type (Minireviews) at: <https://www.wjgnet.com/bpg/GerInfo/291>. Please further revise your manuscript according to the guidelines for revising the content.

(b) Format for Manuscript Revision: Please update the format of your manuscript according to the guidelines and requirements for manuscript revision and the format for manuscript revision. Please visit <https://www.wjgnet.com/bpg/GerInfo/291> for the article type-specific guidelines and formatting examples.

(c) Requirements for article highlights: If your manuscript is an original study (basic study or clinical study), meta-analysis, or systemic review, the "Article Highlights" section should be provided. Detailed writing requirements for "Article Highlights" can be found in the Guidelines and Requirements for Manuscript Revision.

Step 4: References

Please revise the references according to the [Format for references guidelines](#), and be sure to edit the reference using the reference auto-analyser.

Step 5: Footnotes and Figure Legends

(a) Requirements for figures: Please provide decomposable Figures (whose parts are all movable and editable), organize them into a single PowerPoint file, and submit as "**66932-Figures.ppt**" on the system. The figures should be uploaded to the file destination of "Image File".

(b) Requirements for tables: Please provide decomposable Tables (whose parts are all movable and editable), organize them into a single Word file, and submit as "**66932-Tables.docx**" on the system. The tables should be uploaded to the file destination of "Table File".

Step 6: Automatically Generate Full Text Files

Please download the "Full Text File" or click "Preview" to ensure all the contents of the manuscript automatically generated by the system are correct and meet the requirements of the journal.

Step 7: Upload the Revision Files

For all required accompanying documents (listed below), you can begin the uploading process via the F6Publishing system. Then, please download all the uploaded documents to ensure all of them are correct.

- (1) 66932-Answering Reviewers
- (2) 66932-Audio Core Tip
- (3) 66932-Conflict-of-Interest Disclosure Form
- (4) 66932-Copyright License Agreement
- (5) 66932-Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)
- (6) 66932-Non-Native Speakers of English Editing Certificate
- (7) 66932-Video
- (8) 66932-Image File
- (9) 66932-Table File
- (10) 66932-Supplementary Material

If your manuscript has supportive foundations, the approved grant application form(s) or funding agency copy of any approval document(s) must be provided. Otherwise, we will delete the supportive foundations.

If your manuscript has no “Video” or “Supplementary Material”, you don’t need to submit those two types of documents.

[Author Response: Thank you for your comments. We have read the requirements in all the steps, downloaded the relevant accompanying guidance documents and completed all the requirements. In addition, Revision Files applicable to us will be uploaded.](#)

I appreciate for Editors/Reviewers’ warm work earnestly, and hope that the correction will meet with approval.

Yours sincerely
Wei Qian